![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High SVR Rates With the Combination of ABT-493 + ABT-530 for 8
Weeks in Non-Cirrhotic Patients With HCV Genotype 1 or 2 Infection
|
|
|
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Fred Poordad1, Franco Felizarta2, Stanley Wang3, Armen Asatryan3, Tarek Hassanein4, Humberto Aguilar5, Jacob Lalezari6, J Scott Overcash7, Teresa I Ng3, Sandra S Lovell3, Chih-Wei Lin3, Jens Kort3, Federico J Mensa3
1Texas Liver Insti tute, University of Texas Health Science Center, San Antonio, Texas, United States; 2Private practi ce, Bakersfi eld, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States;
5Louisiana Research Center, Shreveport, Louisiana, United States; 6Quest Clinical Research, San Francisco, California, United States; 7eStudySite, San Diego, California, United States
![EASL1](../images/041816/041816-9/EASL1.gif)
![EASL2](../images/041816/041816-9/EASL2.gif)
![EASL3](../images/041816/041816-9/EASL3.gif)
![EASL4](../images/041816/041816-9/EASL4.gif)
![EASL5](../images/041816/041816-9/EASL5.gif)
![EASL6](../images/041816/041816-9/EASL6.gif)
![EASL7](../images/041816/041816-9/EASL7.gif)
![EASL8](../images/041816/041816-9/EASL8.gif)
![EASL9](../images/041816/041816-9/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|